Invivyd (NASDAQ:IVVD) Earns “Buy” Rating from BTIG Research

Invivyd (NASDAQ:IVVD)‘s stock had its “buy” rating restated by analysts at BTIG Research in a report released on Thursday,Benzinga reports. They presently have a $10.00 price target on the stock. BTIG Research’s price objective would indicate a potential upside of 491.72% from the stock’s current price.

Several other equities research analysts have also recently commented on IVVD. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Invivyd in a report on Monday, December 29th. Zacks Research raised Invivyd from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. D. Boral Capital reissued a “hold” rating on shares of Invivyd in a research report on Tuesday, November 25th. Finally, HC Wainwright upped their price objective on shares of Invivyd from $5.00 to $10.00 and gave the company a “buy” rating in a report on Friday, October 31st. Three equities research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, Invivyd has an average rating of “Hold” and an average target price of $8.00.

Invivyd Trading Down 0.6%

Shares of NASDAQ IVVD opened at $1.69 on Thursday. The stock has a market cap of $393.97 million, a PE ratio of -3.60 and a beta of 0.60. Invivyd has a 12-month low of $0.46 and a 12-month high of $3.07. The company has a 50-day moving average of $2.09 and a 200 day moving average of $1.79.

Insider Buying and Selling at Invivyd

In other Invivyd news, insider Julie Green sold 20,964 shares of the stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $33,123.12. Following the completion of the transaction, the insider owned 107,717 shares of the company’s stock, valued at $170,192.86. This trade represents a 16.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, insider Robert D. Allen III sold 19,392 shares of Invivyd stock in a transaction dated Wednesday, February 18th. The shares were sold at an average price of $1.58, for a total transaction of $30,639.36. Following the sale, the insider owned 114,487 shares of the company’s stock, valued at approximately $180,889.46. This represents a 14.48% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders sold 227,172 shares of company stock worth $354,534. Insiders own 25.40% of the company’s stock.

Hedge Funds Weigh In On Invivyd

Hedge funds have recently made changes to their positions in the stock. Courier Capital LLC acquired a new stake in Invivyd in the 4th quarter valued at approximately $25,000. Bronte Capital Management Pty Ltd. purchased a new position in shares of Invivyd during the fourth quarter worth $27,000. Catalyst Funds Management Pty Ltd acquired a new stake in shares of Invivyd in the second quarter valued at $27,000. DRW Securities LLC acquired a new stake in shares of Invivyd in the fourth quarter valued at $27,000. Finally, ProShare Advisors LLC purchased a new stake in shares of Invivyd in the 4th quarter valued at $30,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.